Safety of prolonged use of dienogest (Visanne) with endometriosis
Abstract
To explore the efficiency, safety and tolerability of dienogest for 12 months of treatment of various forms of endometriosis, conducted a study involving 20 patients aged 18 to 45 years (mean age 20.25 ± 3.8 years). All patients suffered surgical treatment of endometriosis varying degrees of distribution. Dienogest treatment was started on day 1 of the first menstrual period after the operation. All patients performed ultrasonography of the pelvic organs. Assess the degree of severity of pain on a visual analog scale. It is also determined by the level of estradiol on day 2-3 of the menstrual cycle before treatment and at 3, 6, 12 months against the backdrop of dienogest therapy. We studied the thrombogenic potential of the blood and blood biochemical parameters in the same periods of time. The study found that Visanna generally well tolerated and is associated with lower incidence of undesirable manifestations.
About the Authors
V. E. Balan
Moscow Regional Research Institute for Obstetrics and Gynecology
Russian Federation
Russian Federation
S. A. Orlova
Moscow Regional Research Institute for Obstetrics and Gynecology
Russian Federation
Russian Federation
Yu. P. Titchenko
Moscow Regional Research Institute for Obstetrics and Gynecology
Russian Federation
Russian Federation
Yu. M. Belaya
Moscow Regional Research Institute for Obstetrics and Gynecology
Russian Federation
Russian Federation
T. S. Budykina
Moscow Regional Research Institute for Obstetrics and Gynecology
Russian Federation
Russian Federation
References
1. Адамян Л. В., Кулаков В. И., Андреева Е. Н. Эндометриозы: Руководство для врачей. Издательство Медицина, 2006,416 с.
2. Hummelshoj L. et al. Update on endometriosis // Women’s Health, 2006. № 2, Vol. 1. P. 53-56.
3. Sinaii N. et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis // Human Reprod., 2002. № 17, Vol. 10. P. 2715-2724.
4. Mounsey A. L., Wilgus A., Slawson D. C. Diagnosis and management of endometriosis // Am. Fam. Phys., 2006. № 74. P. 594-600.
5. Eskenazi B., Warner M. L. Epidemiology of endometriosis // Obstet. Gynecol. Clin. North. Am., 1997. № 24. P. 235-258.
6. Эндометриоз: Диагностика, лечение и реабилитация, клинические рекомендации по ведению больных / Под редакцией Л. В. Адамян. М., 2013. С. 9-37.
7. Ballweg M. L Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe // J. Pediatr. Adolesc. Gynecol., 2003. № 16 (3 Suppl.). P. S21-S26.
8. Loverro G., Carriero C., Rossi A. C., Putignano G., Nicolardi V., Selvaggi L. A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage lll-IVendometriosis. 136,2008, Eur. J. Obstet. Gyneco.l Reprod. Biol., pp. 180-185.
9. Barri P. N., Coroleu B., Tur R., Barri-Soldevila P.N., Rodriguez I. Endometriosis-associated infertility: surgery and IVF, a comprehensive therapeutic approach. 21, 2010, Reprod. Biomed. Online, pp. 179-185.
10. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии / Под ред. В. И. Кулакова, В. Н. Прилепской, B.Е. Радзинского. М., 2007. С. 683-714.
11. Strowitzki T., Faustmann T., Gerlinger C., Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain a 12-week, randomized, double-blind, placebo-controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2010.
12. Schindler A. E., Christensen B., Henkel A., Oettel M., Moore C. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis // Gynecol. Endocrinol., 2006. № 22. Р. 9-17.
13. Momoeda M., Taketani Y. Randomized double-blind, multicentre, parallel-group dose-response study of dienogest in patients with endometriosis // J. Pharmacol. Ther., 2007. № 35. Р. 769-783.
14. Mahutte N. G., Kayisli U., Arici A. Endometriosis is an inflammatory disease. In: Endometriosis in Clinical Practice, ed. D. Olive // Taylor & Francis, 2005. P. 79-88.
15. Fraser I. S. Recognising, understanding and managing endometriosis / / J. Hum. Reprod. Sci., 2008. № 1. P. 56-64.
16. Cosson M., Querleu D., Donnez J. et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study // Fertil. Steril., 2002. № 77. Р. 684-692.
17. Gerlinger C., Endrikat J., Kallischnigg G., Wessel J. Evaluation of menstrual bleeding patterns: a new proposal for a universal guideline based on the analysis of more than 4500 bleeding diaries // Eur. J. Contracept. Reprod. Health Care., 2007. № 12. Р. 203-211.
18. Strowitzki T., Marr J., Gerlinger C., Faustmann T., Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial // Hum. Reprod., 2010. № 25. Р. 633-641.
19. Yoshiaki Ota, Long-term administration of dienogest reduces recurrence after excision of endometrioma, Journal of Endometriosis and Pelvic Pain Disorders 2015; 7 [2]: 63-67
20. Katsuki Y. et al. Animal studies on the endocrinological profile of dienogest, a novel synthetic steroid // Drugs Exp. Clin. Res., 1997. № 23, Vol. 2. Р. 45-62.
21. Nakamura M. et al. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis // Eur. J. Pharmacol., 1999. № 386, Vol. 1. Р. 33-40.
22. Okada H. et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro // Mol. Hum. Reprod., 2001. № 7, Vol.4. Р. 341-347.
Review
For citations:
Balan V.E., Orlova S.A., Titchenko Yu.P., Belaya Yu.M., Budykina T.S. Safety of prolonged use of dienogest (Visanne) with endometriosis. Medical alphabet. 2017;1(3):12-15. (In Russ.)
Views:
1615
Email this article 